Clinical Trial Update: Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating F-627 (Neulasta-controlled) in women with breast cancer undergoing myelotoxic chemotherapy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neutropenia

Drugs mentioned

• F-627
• Neulasta-controlled (pegfilgrastim control agent)

Snippet

Sponsor: EVIVE Biotechnology | Conditions: Breast Cancer, Neutropenia | Phase 3 | Status: COMPLETED | Results posted: 2021-05-07